Repeat surgery in HNF1alpha-inactivated adenomatosis.


Journal

Clinics and research in hepatology and gastroenterology
ISSN: 2210-741X
Titre abrégé: Clin Res Hepatol Gastroenterol
Pays: France
ID NLM: 101553659

Informations de publication

Date de publication:
08 2019
Historique:
received: 08 05 2018
revised: 07 11 2018
accepted: 12 11 2018
pubmed: 25 3 2019
medline: 7 7 2020
entrez: 24 3 2019
Statut: ppublish

Résumé

Stopping oral contraceptives following nodule detection usually prevents further hepatocellular growth (HCA); rare cases of growth have been reported after surgery. The aim of the study was to review our resected HCA cases and their outcomes and more specifically, growth. We retrieved all HCA cases that required a second intervention and HCA growth cases of none resected HCA after resection of one or several HCAs. Out of the 210 resected classified HCA cases, a second resection was performed in 5 cases, 4 of which were in women with HNF1alpha-inactivated adenomatosis (H-adenomatosis) and had a favorable outcome. The fifth case was the occurrence of an inflammatory HCA, 3 years after resection of a previous one. Of the 65 resected HNF1-inactivated HCAs (H-HCAs), the nodules that remained continued to increase very slowly in 3 adenomatosis cases. After surgery, the liver became dysmorphic years later in one case, and the nodules grew but not significantly in another case. After the diagnosis of adenomatosis, progressive growth leads to surgery 12 years later in the last case. These results confirm that, in rare H-adenomatosis, size of nodules may increase very slowly, probably in part through coalescence of micro H-HCAs and leading occasionally to a second resection.

Sections du résumé

BACKGROUND AND AIMS
Stopping oral contraceptives following nodule detection usually prevents further hepatocellular growth (HCA); rare cases of growth have been reported after surgery. The aim of the study was to review our resected HCA cases and their outcomes and more specifically, growth.
METHODS
We retrieved all HCA cases that required a second intervention and HCA growth cases of none resected HCA after resection of one or several HCAs.
RESULTS
Out of the 210 resected classified HCA cases, a second resection was performed in 5 cases, 4 of which were in women with HNF1alpha-inactivated adenomatosis (H-adenomatosis) and had a favorable outcome. The fifth case was the occurrence of an inflammatory HCA, 3 years after resection of a previous one. Of the 65 resected HNF1-inactivated HCAs (H-HCAs), the nodules that remained continued to increase very slowly in 3 adenomatosis cases. After surgery, the liver became dysmorphic years later in one case, and the nodules grew but not significantly in another case. After the diagnosis of adenomatosis, progressive growth leads to surgery 12 years later in the last case.
CONCLUSION
These results confirm that, in rare H-adenomatosis, size of nodules may increase very slowly, probably in part through coalescence of micro H-HCAs and leading occasionally to a second resection.

Identifiants

pubmed: 30902584
pii: S2210-7401(18)30257-2
doi: 10.1016/j.clinre.2018.11.001
pii:
doi:

Substances chimiques

HNF1A protein, human 0
Hepatocyte Nuclear Factor 1-alpha 0
Neoplasm Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

460-467

Informations de copyright

Copyright © 2018. Published by Elsevier Masson SAS.

Auteurs

Charles Balabaud (C)

Inserm, UMR1053 Bordeaux research in translational oncology, université de Bordeaux, Bariton, 33076 Bordeaux, France. Electronic address: charles.balabaud@u-bordeaux.fr.

Christophe Laurent (C)

Service de chirurgie digestive et endocrinienne, centre médico-chirurgical Magellan, Haut-Lévêque hospital, CHU de Bordeaux, 33604 Pessac, France.

Nora Frulio (N)

Department of radiology Magellan 2, Haut-Lévêque hospital, CHU de Bordeaux, 33604 Pessac, France.

Saint Paul Marie Christine (SP)

Pathology department, Pasteur Hospital, CHU de Nice, 06002 Nice, France.

Brigitte Le Bail (B)

Inserm, UMR1053 Bordeaux research in translational oncology, université de Bordeaux, Bariton, 33076 Bordeaux, France; Pathology department, Pellegrin Hospital, CHU de Bordeaux, 33076 Bordeaux France.

Laurent Possenti (L)

Department of hepato-gastroenterology and digestive oncology, Haut-Lévêque hospital, CHU de Bordeaux, 33604 Pessac, France.

Jean Frédéric Blanc (JF)

Inserm, UMR1053 Bordeaux research in translational oncology, université de Bordeaux, Bariton, 33076 Bordeaux, France; Department of hepato-gastroenterology and digestive oncology, Haut-Lévêque hospital, CHU de Bordeaux, 33604 Pessac, France.

Laurence Chiche (L)

Service de chirurgie digestive et endocrinienne, centre médico-chirurgical Magellan, Haut-Lévêque hospital, CHU de Bordeaux, 33604 Pessac, France.

Paulette Bioulac-Sage (P)

Inserm, UMR1053 Bordeaux research in translational oncology, université de Bordeaux, Bariton, 33076 Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH